Leyden Labs Raises $200M in 2021 for a New Approach to Combat Viruses
January 25, 2022 07:00 ET | Leyden Labs
--$140M Series B financing led by Casdin Capital and GV (formerly Google Ventures) with participation from leading global life science investors -- -- Proceeds accelerate development of products...
Leyden Labs Licenses Pan-Influenza Antibody from Janssen
January 18, 2022 07:00 ET | Leyden Labs
AMSTERDAM, The Netherlands and BOSTON, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Leyden Laboratories B.V. (the “Company” or “Leyden Labs”), today announces the development of an intranasal spray protecting...
Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory Viruses
July 21, 2021 09:00 ET | Leyden Labs
NEWPORT, United Kingdom and AMSTERDAM, July 21, 2021 (GLOBE NEWSWIRE) -- Nanopharm Ltd., an Aptar Pharma company and leader in contract research and development of orally inhaled and nasally...
Leyden Labs to Unlock a New Generation of Preventative Medicines against Known and Future Viruses by Securing a €40 Million Series A from GV (formerly Google Ventures), F-Prime and Casdin Capital
March 25, 2021 08:00 ET | Leyden Labs
AMSTERDAM and BOSTON, March 25, 2021 (GLOBE NEWSWIRE) -- Leyden Laboratories B.V., (the "Company" or "Leyden Labs") a company targeting commonalities of viral families to protect humanity from known...